MedTrace Logo

Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

NCT07581418 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-05-12

No results posted yet for this study

Summary

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Methotrexate

Oral methotrexate administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.

DRUG

Tofacitinib

Oral tofacitinib administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

Sponsors & Collaborators

  • Pak Emirates Military Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-12-01
Completion
2026-12-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07581418 on ClinicalTrials.gov